Editas Medicine (EDIT) Revenue & Revenue Breakdown
Editas Medicine Revenue Highlights
00
Main Segment (Y)
Reportable Segment
Editas Medicine Revenue by Period
Editas Medicine Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | -100.00% |
| 2024-12-31 | $32.31M | -58.64% |
| 2023-12-31 | $78.12M | 296.32% |
| 2022-12-31 | $19.71M | -22.83% |
| 2021-12-31 | $25.54M | -71.85% |
| 2020-12-31 | $90.73M | 341.93% |
| 2019-12-31 | $20.53M | -35.71% |
| 2018-12-31 | $31.94M | 132.64% |
| 2017-12-31 | $13.73M | 126.80% |
| 2016-12-31 | $6.05M | 271.58% |
| 2015-12-31 | $1.63M | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Editas Medicine generated - in revenue during NA 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Editas Medicine Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | -100.00% |
| 2025-06-30 | $3.58M | -23.19% |
| 2025-03-31 | $4.66M | -84.78% |
| 2024-12-31 | $30.60M | 50070.49% |
| 2024-09-30 | $61.00K | -88.11% |
| 2024-06-30 | $513.00K | -54.80% |
| 2024-03-31 | $1.14M | -98.11% |
| 2023-12-31 | $60.05M | 1025.36% |
| 2023-09-30 | $5.34M | 84.83% |
| 2023-06-30 | $2.89M | -70.69% |
| 2023-03-31 | $9.85M | 50.72% |
| 2022-12-31 | $6.54M | 15461.90% |
| 2022-09-30 | $42.00K | -99.34% |
| 2022-06-30 | $6.36M | -6.04% |
| 2022-03-31 | $6.77M | -45.70% |
| 2021-12-31 | $12.47M | 101.21% |
| 2021-09-30 | $6.20M | 1535.09% |
| 2021-06-30 | $379.00K | -94.17% |
| 2021-03-31 | $6.50M | -43.09% |
| 2020-12-31 | $11.42M | -81.83% |
| 2020-09-30 | $62.84M | 484.62% |
| 2020-06-30 | $10.75M | 87.82% |
| 2020-03-31 | $5.72M | -53.41% |
| 2019-12-31 | $12.28M | 219.23% |
| 2019-09-30 | $3.85M | 65.15% |
| 2019-06-30 | $2.33M | 12.61% |
| 2019-03-31 | $2.07M | -66.19% |
| 2018-12-31 | $6.12M | -57.86% |
| 2018-09-30 | $14.52M | 96.95% |
| 2018-06-30 | $7.37M | 87.73% |
| 2018-03-31 | $3.93M | 7.09% |
| 2017-12-31 | $3.67M | -41.63% |
| 2017-09-30 | $6.28M | 102.84% |
| 2017-06-30 | $3.10M | 354.11% |
| 2017-03-31 | $682.00K | -24.05% |
| 2016-12-31 | $898.00K | -6.65% |
| 2016-09-30 | $962.00K | -71.61% |
| 2016-06-30 | $3.39M | 320.87% |
| 2016-03-31 | $805.00K | 1.64% |
| 2015-12-31 | $792.00K | 18.21% |
| 2015-09-30 | $670.00K | 301.20% |
| 2015-06-30 | $167.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | - |
Editas Medicine generated - in revenue during Q3 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Editas Medicine Revenue Breakdown
Editas Medicine Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Reportable Segment | $40.52M | $32.31M |
Latest
Editas Medicine's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|---|
| Reportable Segment | $24.74M | $7.54M | $3.58M | $4.66M |
Latest
Editas Medicine's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Editas Medicine Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VNDA | Vanda Pharmaceuticals | $216.10M | $56.26M |
| VYGR | Voyager Therapeutics | $40.37M | $13.37M |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |
| IMMP | Immutep | $3.51M | $2.11M |
| LYEL | Lyell Immunopharma | $36.00K | $15.00K |
| EDIT | Editas Medicine | - | - |
| CABA | Cabaletta Bio | - | - |
| ALLO | Allogene Therapeutics | - | - |
| KYTX | Kyverna Therapeutics | - | - |
| CAPR | Capricor Therapeutics | - | - |
| AVIR | Atea Pharmaceuticals | - | - |